Abstract
Background In a recent randomized double-blind sham-controlled study the Cefaly, a novel transcutaneous supraorbital electrostimulation device, has been successfully used as a prophylactic treatment for episodic migraine. The possible mechanisms of action through which the device is able to induce clinical improvement in migraine are not known. In the present study, we investigated whether Cefaly may act centrally at the thalamocortical/cortical level.
Highlights
In a recent randomized double-blind sham-controlled study the Cefaly®, a novel transcutaneous supraorbital electrostimulation device, has been successfully used as a prophylactic treatment for episodic migraine
Present data might support the hypothesis that Cefaly® acts centrally through increased thalamocortical activity induced by the neurostimulation
It is of obvious interest to verify whether these device-induced changes might persist in the long-term after 3-month daily preventive stimulation, and if they follow clinical improvement
Summary
Transcutaneous supraorbital nerve stimulation enhances somatosensory thalamic activity in migraine between attacks: a central mechanism of clinical efficacy?. Davide Di Lenola1*, Gianluca Coppola, Mariano Serrao, Cherubino Di Lorenzo, Francesco Pierelli. From Abstracts from the 1st Joint ANIRCEF-SISC Congress Rome, Italy. From Abstracts from the 1st Joint ANIRCEF-SISC Congress Rome, Italy. 29-31 October 2015
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
